Search results for "Hazard"

showing 10 items of 1517 documents

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct

ECONOMIC ACTIVITY, CREDIT MARKET CONDITIONS, AND THE HOUSING MARKET

2017

In this paper, we assess the characteristics of the housing market and its main determinants. Using data for 20 industrial countries over the period 1970Q1–2012Q2 and a discrete-time Weibull duration model, we find that the likelihood of the end of a housing boom or a housing bust increases over time. Additionally, we show that the different phases of the housing market cycle are strongly dependent on the economic activity, but credit market conditions are particularly important in the case of housing booms. The empirical findings also indicate that although housing booms have similar lengths in European and non-European countries, housing busts are typically shorter in European countries. …

MacroeconomicsEconomics and Econometrics050208 finance05 social sciencesMonetary policyDuration dependenceSettore SECS-P/02 Politica EconomicaHousing Booms and BustBoomHazardDuration DependenceCubic SplineBust0502 economics and businessEconomicsWeibull ModelBond market050207 economicsDuration (project management)Duration Analysi
researchProduct

Associations of overweight and metabolic health with successful aging: 32-year follow-up of the Helsinki Businessmen Study

2020

Background & aims: Prognostic significance of metabolically healthy overweight and obesity (MHO) is under debate. However the relationship between MHO and health-related quality of life (HRQoL) is less studied. We compared successful aging (longevity plus HRQoL) in men with MHO, metabolically healthy normal weight (MHN) and metabolically unhealthy overweight and obesity (MUO). Methods: In the Helsinki Businessmen Study longitudinal cohort, consisting of men born 1919 to 1934. In 1985/86, overweight (BMI >= 25 kg/m(2)) and metabolic health were determined in 1309 men (median age 60 years). HRQoL was assessed using RAND-36/SF-36 in 2000 and 2007, and all-cause mortality retrieved from registe…

Male0301 basic medicineAgingFITNESSIMPACTRAND-36Successful agingMetabolically healthy overweight and obesityelämänlaatuOverweightCritical Care and Intensive Care MedicineOLD-AGE0302 clinical medicineQuality of lifeQUALITY-OF-LIFEaineenvaihduntaFinlandRISKNutrition and DieteticsHazard ratioylipainoMiddle Aged3. Good healthCARDIOVASCULAR-DISEASEOBESITY3143 Nutritionmedicine.symptomQuality of lifemedicine.medical_specialty030209 endocrinology & metabolism03 medical and health sciencesInternal medicinemedicineHumansAged030109 nutrition & dieteticsMetabolically unhealthy overweight and obesitySuccessful agingbusiness.industryMORTALITYOdds ratioOverweightmedicine.diseaseObesityConfidence intervalBODY-MASS INDEXikääntyminenPHYSICAL-ACTIVITYNonagenariansbusinessBody mass indexFollow-Up StudiesClinical Nutrition
researchProduct

Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study

2018

BACKGROUND: Invasive aspergillosis (IA) is a frequent complication in lung transplant recipients (LTRs). Clinical risk factors for IA have not been fully characterized, especially in the era of extensive anti-fungal prophylaxis. The primary objective of this study was to evaluate the clinical risk factors associated with IA in LTRs. The secondary objective was to assess the mortality in LTRs who had at least 1 episode of IA compared with LTRs who never had experienced IA.METHODS: We conducted an international, multicenter, retrospective cohort study of 900 consecutive adults who received lung transplants between 2005 and 2008 with 4years of follow-up. Risk factors associated with IA were id…

Male0301 basic medicineAntifungal Agentsviruses030230 surgeryAspergillosisanti-fungal prophylaxis; Aspergillus spp; invasive aspergillosis; lung transplant recipient; single-lung transplant; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationCohort StudiesPostoperative Complications0302 clinical medicineRisk Factorshemic and lymphatic diseasesMedicineInvasive Pulmonary AspergillosisFirst episodeMortality rateHazard ratioMiddle Agedembryonic structuresFemaleCardiology and Cardiovascular MedicineLung TransplantationCohort studyAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyanimal structuresAdolescent030106 microbiologyYoung Adult03 medical and health sciencesanti-fungal prophylaxisInternal medicineHumansIntensive care medicineAgedProportional Hazards ModelsRetrospective Studiesinvasive aspergillosisTransplantationbusiness.industryProportional hazards modelAspergillus fumigatusAspergillus spp anti-fungal prophylaxis invasive aspergillosis lung transplant recipient single-lung transplantAspergillus sppRetrospective cohort studybiochemical phenomena metabolism and nutritionmedicine.diseaseSurvival Analysissingle-lung transplantTransplantationSurgerybusinesslung transplant recipientFollow-Up StudiesThe Journal of Heart and Lung Transplantation
researchProduct

Dietary total antioxidant capacity and mortality in the PREDIMED study

2015

PURPOSE: The aim of the present study was to assess the association between the dietary total antioxidant capacity, the dietary intake of different antioxidants and mortality in a Mediterranean population at high cardiovascular disease risk. METHODS: A total of 7,447 subjects from the PREDIMED study (multicenter, parallel group, randomized controlled clinical trial), were analyzed treating data as an observational cohort. Different antioxidant vitamin intake and total dietary antioxidant capacity were calculated from a validated 137-item food frequency questionnaire at baseline and updated yearly. Deaths were ascertained through contact with families and general practitioners, review of med…

Male0301 basic medicineAntioxidantmedicine.medical_treatmentMedicine (miscellaneous)Diet MediterraneanAntioxidantsRisk FactorsSurveys and QuestionnairesSingle-Blind MethodProspective StudiesFood scienceAged 80 and overeducation.field_of_studyNutrition and DieteticsMediterranean RegionVitaminsMiddle AgedCardiovascular DiseasesCohortFemalePREDIMEDmedicine.medical_specialtyPopulationAntioxidant intakeMotor ActivityDietary antioxidant capacityNational Death Index03 medical and health sciencesInternal medicineMortalitatmedicineHumansMortalityeducationAgedProportional Hazards Models030109 nutrition & dieteticsProportional hazards modelbusiness.industryPredimedTrace ElementsClinical trialNutrition AssessmentMultivariate AnalysisObservational studyEnergy IntakebusinessFollow-Up StudiesEuropean Journal of Nutrition
researchProduct

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

2018

Background: Scant real-world data exist on the clinical outcomes associated with the use of bevacizumab-containing chemotherapy (B+CT) in patients with metastatic colorectal cancer (mCRC). The primary objective of the GRETA cohort study was to compare the overall survival (OS) of patients with mCRC treated with first-line B+CT versus chemotherapy (CT) alone, in an Italian clinical practice setting. Materials and Methods: Incident patients with mCRC were identified during the period 2010–2012 from five population-based cancer registries in Italy. Cases were linked to regional health care utilization databases to obtain the entire spectrum of health services provided to each patient. Patients…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabPropensity scoreColorectal cancerHealth Outcomes and Economics of Cancer CarePopulationSettore MED/42 - Igiene Generale E ApplicataCohort StudiesColorectal neoplasm03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSurvival analysiInternal medicineObservational studymedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studybusiness.industryHazard ratioCancerMiddle Agedmedicine.diseaseBevacizumab030104 developmental biologyOncology030220 oncology & carcinogenesisPropensity score matchingCohortFemaleColorectal Neoplasmsbusinessmedicine.drugCohort study
researchProduct